ACLARION

aclarion-logo

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (โ€œMRSโ€), and a proprietary biomarker to optimize clinical treatments. Aclarionโ€™s technology addresses the $134.5B U.S. low back and neck pain market. The Company is currently utilizing Artificial Intelligence (โ€œAIโ€) to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. The Company is also researching the application of AI and machine learning platforms... to analyze both the raw spectroscopy data and the post-processed signal to evaluate whether AI platforms can more efficiently and more effectively associate MRS data with clinical outcomes. The company has conducted its operations since early 2008 on over $3.5 million dollars of Series A Preferred financing. This was raised via private placement โ€œAngelโ€ investments via accredited investors, including from each of the companyโ€™s founders and a long list of world renowned thought leaders in spine surgery, pain management, and imaging/radiology. The company's direction and management continue to be led by its co-founders, and via an expanded team of management and operational professionals - and other consultants - adding further significant experience and acumen in engineering, sales & marketing, reimbursement, and regulatory/quality/clinical affairs relevant to the company's field. The company already achieved many significant development milestones for its primary first investigational product, NociscanTM, involving multiple inventions captured in intellectual property owned by the Company. The company initially sponsored a $1MM/2 year co-development program at UCSF from early 2008 to early 2010. This principally featured feasibility clinical studies to initially develop the technology for use with one initial commercially available high field MR system for robustly acquired and post-processed in vivo MRS data, and to train a diagnostic algorithm based on that MRS data which correlates highly to pain and degeneration per other standard diagnostic controls (e.g. including invasive discogram for pain). The data from this initial investigational clinical development study demonstrated high procedural success for the Nociscan MRS diagnostic platform, with extremely high diagnostic accuracy against standard controls for diagnosing discs as painful vs. non-painful, and was the subject of multiple podium presentations in various medical and scientific society venues. Nocimed's more recent activities and objectives have been to advance Nociscan in next investigational development steps from the successful initial development and feasibility experience enjoyed at UC San Francisco. This has principally involved development for cross-platform use via multiple different MR system platforms from different manufacturers, and while gathering more clinical data for assessing correlations and algorithm training. The company plans to complete this development under an on-going multi-platform, multi-center study that was IRB approved in October 2011 and launched on a first platform (Siemens 3T Verio) in November 2011. While Nociscan is being developed and evaluated for compatible use with various MR systems from multiple manufacturers, the company is using the current study and conducting concurrent negotiations to evaluate which MR system(s) will be chosen for advancement for future trials, regulatory pathways, and ultimate planned commercialization in the future. Upon successful completion of this study, the company plans to freeze the platform design for a first generation planned product offering, and conduct a prospective, multi-center trial to further confirm the robustness of the uses intended for regulatory clearance of the platform. These latter activities are likely to be conducted via a multi-$ million dollar Series B Preferred financing that the company plans to conduct by mid-2011.

#SimilarOrganizations #People #Financial #Website #More

ACLARION

Social Links:

Industry:
Health Care Medical Medical Device Therapeutics

Founded:
2008-01-01

Address:
San Mateo, California, United States

Country:
United States

Website Url:
http://www.aclarion.com

Total Employee:
1+

Status:
Active

Contact:
(650) 241-1741

Email Addresses:
[email protected]

Total Funding:
17.13 M USD

Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail JsDelivr Microsoft Azure DNS US Privacy User Signal Mechanism Google Google Cloud Amazon Route 53 OSS CDN


Similar Organizations

juventas-therapeutics-logo

Juventas Therapeutics

Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.

mediprint-ophthalmics-logo

MediPrint Ophthalmics

MediPrint Ophthalmics is a clinical stage eye care pharmaceutical company.

portal-instruments-logo

Portal Instruments

Portal Instruments is an early stage company that offers medical device.

Current Employees Featured

james-abel_image

James Abel
James Abel VP of Software Engineering @ Aclarion
VP of Software Engineering
2018-05-16

ryan-bond_image

Ryan Bond
Ryan Bond VP of Business Development @ Aclarion
VP of Business Development
2018-12-01

craig-lee_image

Craig Lee
Craig Lee COO @ Aclarion
COO
2018-10-01

brett-lanuti_image

Brett Lanuti
Brett Lanuti CEO @ Aclarion
CEO
2018-01-01

john-claude_image

John Claude
John Claude VP Field Engineer and Regulatory Affairs @ Aclarion
VP Field Engineer and Regulatory Affairs
2016-10-01

not_available_image

David Bradford
David Bradford Founder @ Aclarion
Founder

jeff-lotz_image

Jeff Lotz
Jeff Lotz Founder @ Aclarion
Founder

leilani-ibarolle_image

Leilani Ibarolle
Leilani Ibarolle VP of Finance @ Aclarion
VP of Finance
2019-02-26

Founder


not_available_image

David Bradford

jeff-lotz_image

Jeff Lotz

jim-peacock_image

Jim Peacock

Stock Details


Company's stock symbol is NASDAQ:ACON

Investors List

tech-coast-angels_image

Tech Coast Angels

Tech Coast Angels investment in Venture Round - Aclarion

Official Site Inspections

http://www.aclarion.com Semrush global rank: 8.21 M Semrush visits lastest month: 353

  • Host name: 63.66.206.35.bc.googleusercontent.com
  • IP address: 35.206.66.63
  • Location: Mountain View United States
  • Latitude: 37.4043
  • Longitude: -122.0748
  • Metro Code: 807
  • Timezone: America/Los_Angeles
  • Postal: 94043

Loading ...

More informations about "Aclarion" on Search Engine